Related references
Note: Only part of the references are listed.Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors
A. Gault et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Immune checkpoint inhibitor-related dermatologic adverse events
Amaris N. Geisler et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
Emily Coleman et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Dermatologic Reactions to Immune Checkpoint Inhibitors Skin Toxicities and Immunotherapy
Vincent Sibaud
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy
Veronica J. Shi et al.
JAMA DERMATOLOGY (2016)
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo et al.
JAMA DERMATOLOGY (2015)
Lichen Planopilaris: Update on Diagnosis and Treatment
Philippe Assouly et al.
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2009)
Share Paper
